Francis Wheeler

Cooley advised TBO, a leading global travel distribution platform, on its agreement to acquire Classic Vacations from Arizona-based investment firm, the Najafi Companies.

Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering.

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).

Cooley advised Nanjing Leads Biolabs Co. (Leads Biolabs), a clinical-stage biotechnology company that discovers, develops and commercializes new therapies in oncology, autoimmune and other severe diseases, on its HK$1.29 billion initial public offering (IPO).

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine and patient care through artificial intelligence, on its offering of $650 million aggregate principal amount of 0.75% convertible senior notes due 2030 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.